← Russell 3000 cross-section

WAT WATERS CORP /DE/

Trailing twelve months to 2026-07-04 · as filed 2026-08-11, not restated
Healthcare

Scale

Market cap
$41.6bn
Revenue TTM
$4.6bn
Net income TTM
$166m
Free cash flow
Composite score
35.4
Sector rank
#274

Valuation

P / E
250.4
EV / EBITDA
48.7
EV / sales
9.9
FCF yield
Earnings yield vs 10-yr
-4.33pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
3.6%
EBITDA margin
20.3%
ROE
1.1%
ROIC
1.7%
Revenue growth
52.5%

Insider activity, last 90 days

Net open-market
$-1.44m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Revenue The Company’s revenue increased 113% in the second quarter of 2026, as compared to the second quarter of 2025 and 103% for the first half of 2026 as compared to the first half of 2025, primarily driven by $817 million and $1.3 billion of revenue contributed by the BDS Business for the second quarter and since the Closing Date for the first half of 2026, respectively. Excluding the BDS Business revenue, legacy revenue increased 7% and 10% in the second quarter and first half of 2026, respectively, primarily due to broad-based growth across all product lines and geographical regions. …WATERS CORP /DE/, 10-Q, period ended 2026-07-04, filed 2026-08-11

Read the full passage →